|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Ries LAG, Eisner MP, Kosary CL, et al:
SEER Cancer Statistics Review, 1975–2002. National Cancer
Institute; Bethesda, MD: 2005
|
|
3
|
Goldstraw P, Crowley J, Chansky K, et al:
The IASLC Lung Cancer Staging Project: proposals for the revision
of the TNM stage groupings in the forthcoming (seventh) edition of
the TNM Classification of malignant tumours. J Thorac Oncol.
2:706–714. 2007. View Article : Google Scholar
|
|
4
|
Caglar HB, Baldini EH, Othus M, et al:
Outcomes of patients with stage III nonsmall cell lung cancer
treated with chemotherapy and radiation with and without surgery.
Cancer. 115:4156–4166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoang T, Xu R, Schiller JH, Bonomi P and
Johnson DH: Clinical model to predict survival in chemonaive
patients with advanced non-small-cell lung cancer treated with
third-generation chemotherapy regimens based on eastern cooperative
oncology group data. J Clin Oncol. 23:175–183. 2005. View Article : Google Scholar
|
|
6
|
Blackstock AW, Herndon JE II, Paskett ED,
Perry MC, et al: Outcomes among
African-American/non-African-American patients with advanced
non-small-cell lung carcinoma: report from the Cancer and Leukemia
Group B. Blackstock J Natl Cancer Inst. 94:284–290. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vansteenkiste JF, De Leyn PR, Deneffe GJ,
et al: Survival and prognostic factors in resected N2 non-small
cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group.
Ann Thorac Surg. 63:1441–1450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
No authors listed. Postoperative T1 N0
non-small cell lung cancer. Squamous versus nonsquamous recurrences
The Lung Cancer Study Group. J Thorac Cardiovasc Surg. 94:349–354.
1987.PubMed/NCBI
|
|
9
|
Harpole DH Jr, Herndon JE II, Young WG Jr,
Wolfe WG and Sabiston DC Jr: Stage I nonsmall cell lung cancer. A
multivariate analysis of treatment methods and patterns of
recurrence. Cancer. 76:787–796. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takise A, Kodama T, Shimosato Y, Watanabe
S and Suemasu K: Histopathologic prognostic factors in
adenocarcinomas of the peripheral lung less than 2 cm in diameter.
Cancer. 61:2083–2088. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shields TW: Prognostic significance of
parenchymal lymphatic vessel and blood vessel invasion in carcinoma
of the lung. Surg Gynecol Obstet. 157:185–190. 1983.PubMed/NCBI
|
|
12
|
Berghmans T, Paesmans M and Sculier JP:
Prognostic factors in stage III non-small cell lung cancer: a
review of conventional, metabolic and new biological variables.
Ther Adv Med Oncol. 3:127–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barlési F, Doddoli C, Torre JP, et al:
Comparative prognostic features of stage IIIAN2 and IIIB
non-small-cell lung cancer patients treated with surgery after
induction therapy. Eur J Cardiothorac Surg. 28:629–634.
2005.PubMed/NCBI
|
|
14
|
Riquet M, Bagan P, Le Pimpec Barthes F, et
al: Completely resected non-small cell lung cancer: reconsidering
prognostic value and significance of N2 metastases. Ann Thorac
Surg. 84:1818–1824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kameyama K, Huang CL, Liu D, et al:
Problems related to TNM staging: patients with stage III non-small
cell lung cancer. J Thorac Cardiovasc Surg. 124:503–510. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Albain KS, Swann RS, Rusch VW, et al:
Radiotherapy plus chemotherapy with or without surgical resection
for stage III non-small-cell lung cancer: a phase III randomised
controlled trial. Lancet. 374:379–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niizeki H, Morikawa T, Okushiba S, Kondo S
and Katoh H: Survival and prognostic factors in resected cN2-pN0
non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 10:9–13.
2004.PubMed/NCBI
|
|
18
|
Mitsudomi T, Hamajima N, Ogawa M and
Takahashi T: Prognostic significance of p53 alterations in patients
with non-small cell lung cancer: a meta-analysis. Clin Cancer Res.
6:4055–4063. 2000.PubMed/NCBI
|
|
19
|
Mascaux C, Iannino N, Martin B, et al: The
role of RAS oncogene in survival of patients with lung cancer: a
systematic review of the literature with meta-analysis. Br J
Cancer. 92:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martin B, Paesmans M, Berghmans T, et al:
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a
systematic review of the literature with meta-analysis. Br J
Cancer. 89:55–64. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berghmans T, Paesmans M, Mascaux C, et al:
Thyroid transcription factor 1 - a new prognostic factor in lung
cancer: a meta-analysis. Ann Oncol. 17:1673–1676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakamura H, Kawasaki N, Taguchi M and
Kabasawa K: Survival impact of epidermal growth factor receptor
overexpression in patients with non-small cell lung cancer: a
meta-analysis. Thorax. 61:140–145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meert AP, Martin B, Paesmans M, et al: The
role of HER-2/neu expression on the survival of patients with lung
cancer: a systematic review of the literature. Br J Cancer.
89:959–965. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhan P, Wang J, Lv XJ, et al: Prognostic
value of vascular endothelial growth factor expression in patients
with lung cancer: a systematic review with meta-analysis. J Thorac
Oncol. 4:1094–1103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paesmans M, Berghmans T, Dusart M, et al:
Primary tumor standardized uptake value measured on
fluorodeoxyglucose positron emission tomography is of prognostic
value for survival in non-small cell lung cancer: update of a
systematic review and meta-analysis by the European Lung Cancer
Working Party for the International Association for the Study of
Lung Cancer Staging Project. J Thorac Oncol. 5:612–619. 2010.
|
|
26
|
De Wever W, Vankan Y, Stroobants S and
Verschakelen J: Detection of extrapulmonary lesions with integrated
PET/CT in the staging of lung cancer. Eur Respir J. 29:995–1002.
2007.
|
|
27
|
Antoch G, Stattaus J, Nemat AT, et al:
Non-small cell lung cancer: dual-modality PET/CT in preoperative
staging. Radiology. 229:526–533. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gámez C, Rosell R, Fernández A, et al:
PET/CT fusion scan in lung cancer: current recommendations and
innovations. J Thorac Oncol. 1:74–77. 2006.PubMed/NCBI
|
|
29
|
Nair VS, Krupitskaya Y and Gould MK:
Positron emission tomography 18F-fluorodeoxyglucose uptake and
prognosis in patients with surgically treated, stage I non-small
cell lung cancer: a systematic review. J Thorac Oncol. 4:1473–1479.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pöttgen C, Levegrün S, Theegarten D, et
al: Value of 18F-fluoro-2-deoxy-D-glucose-positron emission
tomography/computed tomography in non-small-cell lung cancer for
prediction of pathologic response and times to relapse after
neoadjuvant chemoradiotherapy. Clin Cancer Res. 12:97–106.
2006.
|
|
31
|
Hoekstra CJ, Stroobants SG, Smit EF, et
al: Prognostic relevance of response evaluation using
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in
patients with locally advanced non-small-cell lung cancer. J Clin
Oncol. 23:8362–8370. 2005.
|
|
32
|
Zhu K, Bruce D, Austin N, Devine A,
Ebeling PR and Prince RL: Randomized controlled trial of the
effects of calcium with or without vitamin D on bone structure and
bone-related chemistry in elderly women with vitamin D
insufficiency. J Bone Miner Res. 23:1343–1348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Beer TM and Myrthue A: Calcitriol in
cancer treatment: from the lab to the clinic. Mol Cancer Ther.
3:373–381. 2004.PubMed/NCBI
|
|
34
|
Higashimoto Y, Ohata M, Nishio K, et al: 1
alpha, 25-dihydroxy vitamin D3 and all-trans-retinoic acid inhibit
the growth of a lung cancer cell line. Anticancer Res.
16:2653–2659. 1996.PubMed/NCBI
|
|
35
|
Wood AW, Chang RL, Huang MT, Uskokovic M
and Cooney AH: 1α,25-dihydroxy vitamin D3 inhibits phorbol
ester-dependent chemical carcinogenesis in mouse skin. Biochem
Biophys Res Commun. 116:605–611. 1983.
|
|
36
|
Ordonez-Moran P, Larriba MJ, Pendas-Franco
N, Aguilera O, Gonzalez-Sancho JM and Munoz A: Vitamin D and
cancer: an update of in vitro and in vivo data. Front Biosci.
10:2723–2749. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hansen CM, Binderup L, Hamberg KJ and
Carlberg C: Vitamin D and cancer: effects of 1,25(OH)2D3 and its
analogs on growth control and tumorigenesis. Front Biosci.
6:820–848. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Trump DL, Hershberger PA, Bernardi RJ, et
al: Anti-tumor activity of calcitriol: pre-clinical and clinical
studies. J Steroid Biochem Mol Biol. 89–90:519–526. 2004.PubMed/NCBI
|
|
39
|
Nakagawa K, Sasaki Y, Kato S, Kubodera N
and Okano T: 22-Oxa-1a,25- dihydroxyvitamin D3 inhibits metastasis
and angiogenesis in lung cancer. Carcinogenesis. 26:1044–1054.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Young MR, Ihm J, Lozano Y, Wright MA and
Prechel MM: Treating tumor-bearing mice with vitamin D3 diminishes
tumor-induced myelopoiesis and associated immunosuppression, and
reduces tumor metastasis and recurrence. Cancer Immunol Immunother.
41:37–45. 1995.PubMed/NCBI
|
|
41
|
Kilkkinen A, Knekt P, Heliövaara M, et al:
Vitamin D status and the risk of lung cancer: a cohort study in
Finland. Cancer Epidemiol Biomarkers Prev. 17:3274–3278. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou W, Heist RS, Liu G, et al: Vitamin D
is associated with improved survival in early-stage non-small cell
lung cancer patients. Cancer Epidemiol Biomarkers Prev.
14:2303–2309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou W, Heist RS, Liu G, Asomaning K, et
al: Circulating 25-hydroxyvitamin D levels predict survival in
early-stage non-small-cell lung cancer patients. J Clin Oncol.
25:479–485. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lim HS, Roychoudhuri R, Peto J, Schwartz
G, Baade P and Møller H: Cancer survival is dependent on season of
diagnosis and sunlight exposure. Int J Cancer. 119:1530–1536. 2006.
View Article : Google Scholar : PubMed/NCBI
|
